Article and Video CATEGORIES

Cancer Journey

Search By

Assistant Professor of Medicine, Harvard Medical School

Thoracic Oncologist, Internal Medicine/Medical Oncology, Massachusetts General Hospital

Dana Farber/Harvard Cancer Center

Lung Cancer Onctalk 2023 - Drs Discussion
A recorded live event where a team of top oncologists discusses emerging concepts and best practices in non-small cell lung cancer (NSCLC).
Author
Ibiayi Dagogo-Jack, MD, Guest Faculty
Image
Lung Cancer OncTalk 2023

At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments.

To watch the complete playlist click here.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora